WallStreetZenWallStreetZen

NASDAQ: ONCT
Oncternal Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for ONCT

Based on 1 analyst offering 12 month price targets for Oncternal Therapeutics Inc.
Min Forecast
$18.00+332.17%
Avg Forecast
$18.00+332.17%
Max Forecast
$18.00+332.17%

Should I buy or sell ONCT stock?

Based on 1 analyst offering ratings for Oncternal Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ONCT stock forecasts and price targets.

ONCT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-08-12

1 of 1

Forecast return on equity

Is ONCT forecast to generate an efficient return?
Company
-127.56%
Industry
-402.71%
Market
58.16%
ONCT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ONCT forecast to generate an efficient return on assets?
Company
-84.23%
Industry
26.38%
ONCT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ONCT earnings per share forecast

What is ONCT's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$11.40
Avg 2 year Forecast
-$9.19
Avg 3 year Forecast
-$6.16

ONCT revenue forecast

What is ONCT's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$1.7M-8.67%
Avg 2 year Forecast
$700.0k-62.08%
Avg 3 year Forecast
$1.0M-45.83%
ONCT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ONCT revenue growth forecast

How is ONCT forecast to perform vs Biotechnology companies and vs the US market?
Company
-30.71%
Industry
34.75%
Market
9.32%
ONCT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ONCT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ONCT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ONCT$4.17$18.00+332.17%Buy
DOMH$1.96N/AN/A
CDT$0.13N/AN/A
TENX$3.74N/AN/A
GLTO$11.79$225.00+1,809.21%Buy
View Top Biotech Stocks

Oncternal Therapeutics Stock Forecast FAQ

Is Oncternal Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: ONCT) stock is to Buy ONCT stock.

Out of 1 analyst, 0 (0%) are recommending ONCT as a Strong Buy, 1 (100%) are recommending ONCT as a Buy, 0 (0%) are recommending ONCT as a Hold, 0 (0%) are recommending ONCT as a Sell, and 0 (0%) are recommending ONCT as a Strong Sell.

If you're new to stock investing, here's how to buy Oncternal Therapeutics stock.

What is ONCT's earnings growth forecast for 2024-2026?

(NASDAQ: ONCT) Oncternal Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.16%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.98%.

Oncternal Therapeutics's earnings in 2024 is -$35,973,000.On average, 3 Wall Street analysts forecast ONCT's earnings for 2024 to be -$33,739,953, with the lowest ONCT earnings forecast at -$36,788,387, and the highest ONCT earnings forecast at -$30,869,097. On average, 2 Wall Street analysts forecast ONCT's earnings for 2025 to be -$27,184,339, with the lowest ONCT earnings forecast at -$30,336,361, and the highest ONCT earnings forecast at -$24,032,317.

In 2026, ONCT is forecast to generate -$18,231,413 in earnings, with the lowest earnings forecast at -$18,231,413 and the highest earnings forecast at -$18,231,413.

What is ONCT's revenue growth forecast for 2024-2026?

(NASDAQ: ONCT) Oncternal Therapeutics's forecast annual revenue growth rate of -30.71% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.75%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.32%.

Oncternal Therapeutics's revenue in 2024 is $1,846,000.On average, 3 Wall Street analysts forecast ONCT's revenue for 2024 to be $4,989,961, with the lowest ONCT revenue forecast at $4,054,714, and the highest ONCT revenue forecast at $5,682,518. On average, 2 Wall Street analysts forecast ONCT's revenue for 2025 to be $2,071,752, with the lowest ONCT revenue forecast at $1,775,787, and the highest ONCT revenue forecast at $2,367,716.

In 2026, ONCT is forecast to generate $2,959,645 in revenue, with the lowest revenue forecast at $2,959,645 and the highest revenue forecast at $2,959,645.

What is ONCT's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: ONCT) forecast ROA is -84.23%, which is lower than the forecast US Biotechnology industry average of 26.38%.

What is ONCT's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ONCT price target, the average ONCT price target is $18.00, with the highest ONCT stock price forecast at $18.00 and the lowest ONCT stock price forecast at $18.00.

The Wall Street analyst predicted that Oncternal Therapeutics's share price could reach $18.00 by Aug 12, 2025. The average Oncternal Therapeutics stock price prediction forecasts a potential upside of 332.17% from the current ONCT share price of $4.17.

What is ONCT's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: ONCT) Oncternal Therapeutics's current Earnings Per Share (EPS) is -$12.15. On average, analysts forecast that ONCT's EPS will be -$11.40 for 2024, with the lowest EPS forecast at -$12.43, and the highest EPS forecast at -$10.43. On average, analysts forecast that ONCT's EPS will be -$9.19 for 2025, with the lowest EPS forecast at -$10.25, and the highest EPS forecast at -$8.12. In 2026, ONCT's EPS is forecast to hit -$6.16 (min: -$6.16, max: -$6.16).

What is ONCT's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: ONCT) forecast ROE is -127.56%, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.